| Similar Articles |
|---|
 |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life.   |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
October 31, 2006
Brian Gorman |
Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride. |
The Motley Fool
August 11, 2006
Brian Gorman |
PAREXEL Takes It Up a Notch The company reported higher profitability in the fourth quarter, and management expects the trend to continue. Investors, is this worth a closer look? |
The Motley Fool
April 28, 2006
Brian Gorman |
Kendle Stays Hot The small contract research outfit seems like a safe bet in the near term, but investors should closely monitor the firm's performance. |
The Motley Fool
April 20, 2011
Brandon Glenn |
Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle. |
The Motley Fool
April 27, 2006
Brian Gorman |
PAREXEL Can Do Better Despite heartening recent results, the drug research company's profitability could be better. These shares aren't terribly cheap and it appears that investors' expectations are running high. |
Bio-IT World
April 2007
Deborah Borfitz |
EDC Guru Moves from Novartis to Kendle The publicly owned clinical research organization Kendle recently brought the pragmatic Sylva Collins on board to provide leadership for its global biometrics offerings and help it become "the unparalleled leader in e-clinical services." |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution. |
The Motley Fool
May 10, 2006
Brian Gorman |
Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now. |
